Rituxan Patent Survives Celltrion, Pfizer PTAB Challenges
The Patent Trial and Appeal Board on Wednesday upheld the validity of a patent covering Biogen Inc. and Genentech Inc.'s rheumatoid arthritis biologic Rituxan, shooting down combined challenges from Celltrion Inc....To view the full article, register now.
Already a subscriber? Click here to view full article